Introducing PhaseV's AI-Based Trial Optimizer on AWS Marketplace to Transform Clinical Trials

PhaseV's AI-Powered Trial Optimizer on AWS Marketplace

In a major advancement for the clinical research industry, PhaseV has unveiled its AI-driven Trial Optimizer platform, now available on Amazon Web Services (AWS) Marketplace. This innovative platform is designed to revolutionize the way clinical trials are planned and executed, ultimately enhancing efficiency and feasibility for biopharma companies and Contract Research Organizations (CROs).

A Game Changer in Clinical Trials

The launch of PhaseV’s Trial Optimizer represents a significant milestone aimed at addressing the high failure rates commonly seen in clinical trials, which currently stand at approximately 90%. By integrating advanced artificial intelligence (AI) and machine learning (ML) technologies, the platform significantly improves the chances of success, reduces necessary patient sample sizes, and shortens the overall duration of trials.

Dr. Raviv Pryluk, CEO and Co-Founder of PhaseV, emphasized the importance of this launch: "Bringing Trial Optimizer to AWS Marketplace is a significant milestone for us and, more importantly, for our customers across the globe. With this new platform, customers can leverage AWS’s secure infrastructure to access our robust AI capabilities from anywhere." This enhancement not only aids in expediting the clinical development pipeline but also facilitates quicker access to transformative therapies for patients.

How It Works

PhaseV's Trial Optimizer is engineered to assist clinical trial sponsors in designing, exploring, evaluating, and optimizing trial protocols. It supports a range of methodologies, including fixed, adaptive, and Bayesian approaches, making it versatile in meeting various clinical study requirements. By efficiently integrating multiple data sources—both provided by sponsors and external datasets—the platform helps organizations navigate the complexities involved in trial design, including cost, power analysis, trial duration, and adaptability.

One of the standout features of the platform is its sophisticated algorithm, which generates optimized trial design recommendations. These recommendations cover essential elements such as sample size reduction, allocation of treatment effects during trials, and timelines for interim analyses. As a result, teams can evaluate various design options, ensuring that their strategies align with specific project goals and constraints.

Proven Impact on Trial Efficiency

To date, PhaseV's initiatives have yielded impressive results, with documented reductions in patient recruitment time and trial duration by as much as 40%. Additionally, development costs have been slashed by up to 50%, while the probability of trial success has increased by over 30%. This makes PhaseV's Trial Optimizer a critical asset for stakeholders involved in clinical operations, clinical development, biostatistics, and data science. Its design encourages collaboration and joint decision-making, thereby enhancing the overall efficiency of trial execution.

Advanced Simulation Capabilities

The platform features a Rapid Simulation Engine that executes millions of simulations within minutes, allowing researchers to optimize any trial design quickly. Visual results generated by this engine aid in effortless interpretation, providing early insights into potential adaptive interventions such as response-adaptive randomization, sample size re-estimation, and the strategic dropping of trial arms.

Moreover, the platform incorporates a Causal-to-Design feature, integrating insights from previous trials to optimize criteria for participant inclusion and exclusion. Additionally, it can instantaneously model average placebo response rates through analysis of relevant study and real-world data. These advanced modalities enhance the effectiveness and accuracy of trial designs, making PhaseV’s platform an invaluable tool for the pharmaceutical industry.

Conclusion

The availability of PhaseV’s Trial Optimizer on AWS Marketplace marks a transformative moment in clinical trial design. By making state-of-the-art AI tools readily available, biopharma companies and CROs can now optimize their clinical trials more efficiently and cost-effectively than ever before. As the healthcare landscape continues to evolve, PhaseV remains committed to pushing the boundaries of what's possible in clinical development, striving to bring effective therapies to the patients who need them most.

For further information about PhaseV and its latest offerings, visit www.PhaseVTrials.com.